HBV DNA高载量的肝细胞癌患者肝癌根治术后抗病毒治疗疗效观察

丁晨; 潘凡; 胡还章; 熊日晖; 李嵩; 江艺; 潘晨

doi:10.3969/j.issn.1001-5256.2014.07.021

HBV DNA高载量的肝细胞癌患者肝癌根治术后抗病毒治疗疗效观察

DOI: 10.3969/j.issn.1001-5256.2014.07.021

1. 福建医科大学福总临床医学院
2. 南京军区福州总医院肝胆外科
3. 福州市传染病医院

基金项目:

军区医学科研重大专项资助项目(11Z033)；福建省自然科学基金重点资助项目(2011Y0046)；

详细信息

中图分类号: R735.7
计量
- 文章访问数: 2417
- HTML全文浏览量: 17
- PDF下载量: 571
- 被引次数: 0
出版历程
- 收稿日期: 2013-11-21
- 出版日期: 2014-07-20

Efficacy of antiviral therapy in hepatocellular carcinoma patients with high HBV DNA levels after radical resection

School of Clinical Medicine, Fuzhou General Hospital of Nanjing Military Region, Fujian Medical University

Research funding:

摘要

摘要:
目的评估抗病毒治疗对HBV DNA高载量肝细胞癌（HCC）患者根治术后的疗效。方法回顾性分析2007年1月-2010年1月行肝癌根治术的113例伴HBV DNA高载量HCC患者的临床资料,其中74例行抗病毒治疗（治疗组）,39例未行任何抗病毒治疗（对照组）,均给予基础保肝、支持治疗。对所有患者进行随访,比较2组患者术后HBV DNA定量、肿瘤复发率及生存率差异。组间比较采用t检验或χ2检验,Kaplan-Meier法分析术后生存率,Log-rank检验比较2组术后生存。结果治疗组术后HBV DNA载量持续下降,术后6、12、24个月与术前比较,差异均有统计学意义（t值分别为:14.38、18.50、16.22,P<0.05）,治疗组与对照组HBV DNA载量分别在术后6、12、24个月差异有统计学意义（t值分别为:13.19、24.20、14.15,P<0.05）。2组患者术后3年无瘤生存率差异有统计学意义（P=0.029）。治疗组与对照组的1、2、3年累计生存率分别为:95.95%、85.14%、75.68%和87.18%、69.23%、53.85%,2组术后3年累计生存...
- 癌,肝细胞 /
- 抗病毒药 /
- 病毒载量 /
- 肝炎病毒,乙型
Abstract:
Objective To evaluate the efficacy of antiviral therapy in hepatocellular carcinoma (HCC) patients with high HBV DNA levels after radical resection. Methods A retrospective analysis was performed on the clinical data of 113 HCC patients with high HBV DNA levels who underwent radical resection from January 2007 to January 2010. These patients were divided into treatment group (n = 74) and control group (n = 39) . In addition to liver- protecting therapy and supportive care, antiviral therapy was given to the treatment group, but not in the control group. All patients were followed up after operation, and the two groups were compared in terms of HBV DNA level, tumor recurrence rate, and survival rate. Comparison between the two groups was made by t test or chi- square test; the Kaplan- Meier method was used to calculate postoperative survival rates, and the log- rank test was used for survival difference analysis. Results After operation, the treatment group had a continuously decreased HBV DNA level, which was significantly lower at 6, 12, and 24 months after operation than before operation (t = 14. 38, 18. 50, 16. 22, P < 0. 05) ; there were significant differences in HBV DNA levels at 6, 12, and 24 months after operation between the treatment group and control group ( t = 13. 19, 24. 20, 14. 15, P < 0. 05) . The 3- year disease- free survival (DFS) rate showed significant difference between the two groups after operation (P =0.029) . The 1-, 2-, and 3-year cumulative survival rates were 95. 95%, 85. 14%, and 75. 68%, respectively, in the treatment group and 87. 18%, 69. 23%, and 53. 85%, respectively, in the control group; the treatment group had a significantly higher 3- year cumulative survival rate than the control group (P = 0. 016) .Conclusion Antiviral therapy can increase 3- year DFS rate and prolong postoperative survival in HCC patients with high HBV DNA levels after radical resection. Thus, antiviral therapy should be performed early, regularly, and persistently in HCC patients with high HBV DNA levels.
- carcinoma, hepatocellular /
- antiviral agents /
- viral load /
- hepatitis B virus

HTML全文

参考文献(13)

[1] YUEN MF, HOU JL, CHUTAPUTTI A.Hepatocellular carcinoma in the Asia pacific region[J].J Gastroenterol Hepatol, 2009, 24 (3) :346-353.

[2]LIN H, VAN DEN ESSCHERT J, LIU C, et al.Systematic review of hepatocellular adenoma in China and other regions[J].J Gastroenterol Hepatol, 2011, 26 (1) :28-35.

[3]YUN FL, J HK, TEERHA PIRATVISUTH, et al.Asian-pacific consensus statement on the management of chronic hepatitis B:a2012 update[J].J Clin Hepatol, 2012, 28 (8) :641-661. (in Chinese) 亚太肝病学会慢性乙型肝炎治疗共识工作组.亚太地区慢性乙型肝炎治疗共识 (2012最新版) [J].临床肝胆病杂志, 2012, 28 (8) :641-661.

[4]HAN Y, ZHU JY.Risk factor's survelliance and treatment for hepatocellular carcinoma in cirrhosis[J].Chin J Pract Intern Med, 2013, 33 (9) :694-697. (in Chinese) 韩英, 朱疆依.肝硬化并发肝癌危险因素筛查及综合治疗[J].中国实用内科杂志, 2013, 33 (9) :694-697.

[5]WANG YH, LIU YX.Tumor staging scheme, radical resection criterion and prognostic index of preimary liver cancer[J].Chin J Hepatobiliary Surg, 2003, 9 (1) :3-7. (in Chinese) 王悦华, 刘永雄.原发性肝癌的分期、根治切除标准及预后指标[J].中华肝胆外科杂志, 2003, 9 (1) :3-7.

[6]CHUMA M, HIGE S, KAMIYAMA T, et al.The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma[J].J Gastroenterol, 2009, 44 (9) :991-999.

[7]ISHIKAWA T.Clinical features of hepatitis B virus-related hepatocellular carcinoma[J].World J Gastroenterol, 2010, 16 (20) :2463-2467.

[8] CHEN CJ, YANG HI, LLOEJE UH.Hepatitis B virus DNA levels and outcomes in chronic hepatitis B[J].Hepatology, 2009, 49 (Suppl 5) :s72-s84.

[9] HUANG L, LI J, LAU WY, et al.Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma[J].J Gastroenterol Hepatol, 2012, 27 (1) :158-164.

[10] WU CY, CHEN YJ, HO HJ, et al.Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection[J].JAMA, 2012, 308 (18) :1906-1913.

[11]GUO XP, LIU YW, WANG W, et al.Treatment of liver cirrhosis with postoperative hepatocellular carcinoma with nucleoside analog[J].J Clin Hepatol, 2010, 26 (4) :425-427. (in Chinese) 郭西萍, 刘彦威, 王婉, 等.核苷类抗病毒治疗伴活动性肝硬化肝癌术后的临床观察[J].临床肝胆病杂志, 2010, 26 (4) :425-427.

[12]LI GS, LIU GH, ZHEN H.Application value of antiviral therapy for liver cancer patients infected with hepatitis B virus undergoing radical resection[J].Chin J Gen Surg, 2013, 22 (7) :880-884. (in Chinese) 李巨仕, 刘国华, 郑核.抗病毒治疗对行根治切除术肝癌合并乙肝病毒感染患者的应用价值[J].中国普通外科杂志, 2013, 22 (7) :880-884.

[13]GOU W, WANG YL.Clinical efficacy of entecavir in treatment of hepatogenous diabetes[J].J Clin Hepatol, 2013, 29 (6) :456-458. (in Chinese) 苟卫, 王燕玲.恩替卡韦治疗乙型肝炎肝硬化合并肝源性糖尿病的临床观察[J].临床肝胆病杂志, 2013, 29 (6) :456-458.

施引文献

资源附件(0)

访问统计